[go: up one dir, main page]

PE20091364A1 - Proceso para la preparacion de inhibidores de nep - Google Patents

Proceso para la preparacion de inhibidores de nep

Info

Publication number
PE20091364A1
PE20091364A1 PE2009000047A PE2009000047A PE20091364A1 PE 20091364 A1 PE20091364 A1 PE 20091364A1 PE 2009000047 A PE2009000047 A PE 2009000047A PE 2009000047 A PE2009000047 A PE 2009000047A PE 20091364 A1 PE20091364 A1 PE 20091364A1
Authority
PE
Peru
Prior art keywords
formula
compound
preparation
alkaline
ammonium
Prior art date
Application number
PE2009000047A
Other languages
English (en)
Inventor
David Hook
Daniel Kaufmann
Erhard Bappert
Philippe Polleux
Bernhard Riss
Matthias Napp
Jonathan Medlock
Antonio Zanotti-Gerosa
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091364A1 publication Critical patent/PE20091364A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UN PROCESO PARA LA PREPARACION DE UN COMPUESTO DE FORMULA (7) DONDE R1 ES H O UN GRUPO PROTECTOR DE N; R6 Y R7 SON CADA UNO ALQUILO, ARILO, ARIL-ALQUILO, CICLOALQUILO, ENTRE OTROS; EN DONDE DICHO PROCESO COMPRENDE: A) HACER REACCIONAR UN COMPUESTO DE FORMULA (8) i) CON UNA AMINA DE FORMULA (13), (14) O (15) Y OPCIONALMENTE UNA SAL DE METAL ALCALINO, DE AMONIO, ENTRE OTROS; ii) CON UN COMPUESTO PREPARADO CON LA MEZCLA DE UN COMPUESTO DE FORMULA (18) CON UN ALCOHOLATO DE FORMULA M-O-R8 Y OPCIONALMENTE TRATADO CON UNA SAL M1X'; O iii) CON MEZCLAS DE LOS MISMOS; EN DONDE R8 ES CARBOXILATO O TRIBROMURO; X Y X' SON CADA UNO UN ANION TAL COMO HALURO, PERCLORATO, ENTRE OTROS; M ES UN METAL ALCALINO O ALCALINOTERREO; M1 ES UN METAL ALCALINO, AMONIO, ENTRE OTROS. DICHOS COMPUESTOS SON INTERMEDIARIOS PARA LA PREPARACION DE UN COMPUESTO DE FORMULA (1) DONDE R3 ES CARBOXILO O ESTER, QUE INHIBEN LA ENDOPEPTIDASA NEUTRA (NEP)
PE2009000047A 2008-01-17 2009-01-15 Proceso para la preparacion de inhibidores de nep PE20091364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08150353 2008-01-17

Publications (1)

Publication Number Publication Date
PE20091364A1 true PE20091364A1 (es) 2009-10-13

Family

ID=40758693

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000047A PE20091364A1 (es) 2008-01-17 2009-01-15 Proceso para la preparacion de inhibidores de nep

Country Status (29)

Country Link
US (4) US8580974B2 (es)
EP (1) EP2245009B1 (es)
JP (2) JP5739667B2 (es)
KR (1) KR101587668B1 (es)
CN (2) CN101952249B (es)
AR (1) AR070176A1 (es)
AU (1) AU2009204759B2 (es)
BR (1) BRPI0906764A2 (es)
CA (1) CA2711529C (es)
CL (1) CL2009000089A1 (es)
CO (1) CO6290677A2 (es)
EC (1) ECSP10010405A (es)
ES (1) ES2602564T3 (es)
GT (1) GT201000211A (es)
HU (1) HUE030606T2 (es)
IL (1) IL206664A0 (es)
MA (1) MA31951B1 (es)
MX (1) MX2010007842A (es)
MY (1) MY169425A (es)
NZ (2) NZ600119A (es)
PE (1) PE20091364A1 (es)
PL (1) PL2245009T3 (es)
PT (1) PT2245009T (es)
RU (2) RU2513521C2 (es)
SG (1) SG187491A1 (es)
SI (1) SI2245009T1 (es)
TN (1) TN2010000304A1 (es)
TW (1) TWI422370B (es)
WO (1) WO2009090251A2 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
WO2011035569A1 (en) 2009-09-23 2011-03-31 Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Process for manufacture of n-acylbphenyl alanine
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
ES2523734T3 (es) 2009-05-28 2014-12-01 Novartis Ag Derivados aminopropiónicos sustituidos como inhibidores de neprilisina
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN102712585B (zh) * 2010-01-22 2015-06-24 诺华股份有限公司 中性内肽酶抑制剂中间体和其制备方法
CN103080077B (zh) * 2010-08-23 2015-06-10 诺华股份有限公司 用于制造nep抑制剂的中间体的制备工艺
JP6002133B2 (ja) * 2010-08-23 2016-10-05 ノバルティス アーゲー Ｎｅｐ阻害剤の製造に有用な中間体の新規調製方法
EP2609075B1 (en) * 2010-08-23 2016-03-16 Novartis AG Process for the preparation of intermediates for the manufacture of nep inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ME02295B (me) 2010-12-15 2016-02-20 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
CN103261168B (zh) 2010-12-15 2015-08-05 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
SG192815A1 (en) 2011-02-17 2013-09-30 Theravance Inc Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012154249A1 (en) 2011-02-17 2012-11-15 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012166389A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
EP2714662B1 (en) 2011-05-31 2017-10-11 Theravance Biopharma R&D IP, LLC Neprilysin inhibitors
JP5959075B2 (ja) 2011-05-31 2016-08-02 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ネプリライシン阻害剤
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
CN104350052B (zh) 2012-05-31 2017-05-31 施万生物制药研发Ip有限责任公司 一氧化氮供体脑啡肽酶抑制剂
US8871792B2 (en) 2012-06-08 2014-10-28 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
SG11201408094YA (en) 2012-06-08 2015-01-29 Theravance Biopharma R & D Ip Llc Neprilysin inhibitors
HUE031301T2 (hu) 2012-08-08 2017-07-28 Theravance Biopharma R&D Ip Llc Neprilizin inhibitorok
JP6301371B2 (ja) 2013-02-14 2018-04-11 ノバルティス アーゲー インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体
MX367525B (es) 2013-02-14 2019-08-26 Novartis Ag Derivados de ácido bisfenil-butanoico fosfónico sustituido como inhibidores de la endopeptidasa neutra (nep).
SMT201700368T1 (it) 2013-03-05 2017-09-07 Theravance Biopharma R&D Ip Llc Inibitori di neprilisina
ES2765511T3 (es) * 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
WO2015116786A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CN105960398A (zh) 2014-01-30 2016-09-21 施万生物制药研发Ip有限责任公司 5-联苯-4-杂芳基羰基氨基-戊酸衍生物作为脑啡肽酶抑制剂
EP3218351B1 (en) 2014-11-14 2019-06-19 Zentiva K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
WO2016097242A1 (de) * 2014-12-19 2016-06-23 Basf Se Verfahren zur herstellung optisch aktiver carbonylverbindungen
US9433598B2 (en) 2015-02-11 2016-09-06 Theravance Biopharma R&D Ip, Llc (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
HRP20210040T1 (hr) 2015-02-19 2021-04-02 Theravance Biopharma R&D Ip, Llc (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
CN106146351B (zh) * 2015-04-03 2020-09-11 博瑞生物医药（苏州）股份有限公司 制备联芳基取代的4-氨基-丁酸或其衍生物的方法
CN105061263B (zh) * 2015-08-11 2017-03-15 苏州楚凯药业有限公司 一种nep抑制剂中间体的制备方法
CN105152980B (zh) * 2015-09-11 2017-03-29 浙江永宁药业股份有限公司 N‑叔丁氧羰基‑（4s）‑（对苯基苯基甲基）‑4‑氨基‑（2r）‑甲基丁酸的手性制备方法
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
KR102763706B1 (ko) 2015-12-10 2025-02-07 노파르티스 아게 신규 방법 및 중간체
MX2018007129A (es) 2015-12-11 2018-11-09 Zentiva Ks Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
RS62172B1 (sr) 2016-03-08 2021-08-31 Theravance Biopharma R&D Ip Llc Kristalna (2s,4r)-5-(5’-hloro-2-fluoro-[1,1’-bifenil]-4-il)-2-(etoksimetil)-4-(3-hidroksi izoksazol-5-karboksamido)-2-metilpentanska kiselina i njene upotrebe
JP6944473B2 (ja) 2016-07-05 2021-10-06 ノバルティス アーゲー 初期サクビトリル中間体のための新規な方法
US10851059B2 (en) 2016-08-17 2020-12-01 Novartis Ag Processes and intermediates for NEP inhibitor synthesis
WO2018116203A1 (en) 2016-12-23 2018-06-28 Novartis Ag New process for early sacubitril intermediates
EP3421455B1 (en) * 2017-06-29 2019-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib
CN109912508B (zh) * 2019-04-30 2022-08-12 上海天慈国际药业有限公司 一种右美托咪定及其盐酸盐的制备方法
CN110878039A (zh) * 2019-12-18 2020-03-13 株洲千金药业股份有限公司 一种沙库巴曲缬沙坦钠杂质的制备方法
CN115611857B (zh) * 2022-09-09 2024-05-31 上海伍夫科技有限公司 一种2-甲基-5-（1-甲基吡咯烷-2-基）吡啶的制备方法
CN115772088A (zh) * 2022-12-28 2023-03-10 海门瑞一医药科技有限公司 一种叔丁氧基（双二甲胺基）甲烷的制备方法
CN117510376A (zh) * 2023-10-17 2024-02-06 四川新迪生物制药有限公司 一种手性联芳基取代的4-氨基-丁酸及其衍生物的制备方法
WO2025164594A1 (ja) * 2024-01-29 2025-08-07 高砂香料工業株式会社 ルテニウム－ジホスフィン－カルボキシラート錯体及びその製造方法
CN118239990B (zh) * 2024-05-28 2025-03-14 北京元延医药科技股份有限公司 不对称氢化催化合成药物的稀有贵金属和手性膦的配合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3164237D1 (en) 1980-12-23 1984-07-19 Air Ind Thermo-electrical plants
US5250552A (en) 1991-05-09 1993-10-05 Warner-Lambert Company 3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents
US5250522A (en) 1992-10-09 1993-10-05 Ciba-Geigy Corporation Phosphono/biaryl substituted amino acid derivatives
FR2688503B1 (fr) 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
EP0550313A1 (fr) 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB0402262D0 (en) 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1903027A1 (en) 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
TWI413638B (zh) * 2007-01-12 2013-11-01 Novartis Ag 新穎方法
US8980833B2 (en) 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
CN102712585B (zh) * 2010-01-22 2015-06-24 诺华股份有限公司 中性内肽酶抑制剂中间体和其制备方法
EP2609075B1 (en) * 2010-08-23 2016-03-16 Novartis AG Process for the preparation of intermediates for the manufacture of nep inhibitors
JP6002133B2 (ja) * 2010-08-23 2016-10-05 ノバルティス アーゲー Ｎｅｐ阻害剤の製造に有用な中間体の新規調製方法

Also Published As

Publication number Publication date
EP2245009A2 (en) 2010-11-03
CA2711529A1 (en) 2009-07-23
US9403766B2 (en) 2016-08-02
RU2013148670A (ru) 2015-05-10
RU2636936C2 (ru) 2017-11-29
JP5739667B2 (ja) 2015-06-24
MA31951B1 (fr) 2010-12-01
KR101587668B1 (ko) 2016-01-22
WO2009090251A2 (en) 2009-07-23
SI2245009T1 (sl) 2016-12-30
MX2010007842A (es) 2010-08-09
TN2010000304A1 (en) 2011-11-11
US8580974B2 (en) 2013-11-12
SG187491A1 (en) 2013-02-28
TWI422370B (zh) 2014-01-11
CO6290677A2 (es) 2011-06-20
BRPI0906764A2 (pt) 2015-08-18
HUE030606T2 (en) 2017-05-29
JP2014070076A (ja) 2014-04-21
US20160060217A1 (en) 2016-03-03
AU2009204759B2 (en) 2012-06-07
EP2245009B1 (en) 2016-08-10
PT2245009T (pt) 2016-11-10
CN103483236B (zh) 2016-09-28
ECSP10010405A (es) 2010-09-30
NZ600119A (en) 2013-07-26
KR20100119867A (ko) 2010-11-11
ES2602564T3 (es) 2017-02-21
WO2009090251A3 (en) 2009-12-23
CN103483236A (zh) 2014-01-01
AU2009204759A1 (en) 2009-07-23
US20110046397A1 (en) 2011-02-24
MY169425A (en) 2019-04-04
RU2010133903A (ru) 2012-02-27
IL206664A0 (en) 2010-12-30
US20140243546A1 (en) 2014-08-28
NZ586657A (en) 2012-06-29
CN101952249B (zh) 2013-10-16
PL2245009T3 (pl) 2017-06-30
TW200938188A (en) 2009-09-16
CA2711529C (en) 2016-11-22
RU2513521C2 (ru) 2014-04-20
CN101952249A (zh) 2011-01-19
JP5800882B2 (ja) 2015-10-28
US9061973B2 (en) 2015-06-23
GT201000211A (es) 2014-03-14
JP2011510097A (ja) 2011-03-31
CL2009000089A1 (es) 2010-01-22
US9227934B2 (en) 2016-01-05
US20150246881A1 (en) 2015-09-03
AR070176A1 (es) 2010-03-17

Similar Documents

Publication Publication Date Title
PE20091364A1 (es) Proceso para la preparacion de inhibidores de nep
BR112012018408A2 (pt) composição do combustível diesel, pacote do aditivo, uso de um aditivo e uso de uma composição do combustível diesel.
AR081385A1 (es) Composiciones metodo y uso
PH12016502037A1 (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR048669A1 (es) Derivados biciclicos de bisamida
CR20190244A (es) Agentes control de plaga
PE20040956A1 (es) Procedimiento para preparar la sal 5-[(r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil]-8-hidroxi-(1h)-quinolin-2-ona
ECSP21016009A (es) Inhibidores de sarcómeros cardíacos
UY33357A (es) Uracilos herbicidas
PE20050088A1 (es) Proceso para la fabricacion de valsartan
BR112012024403A2 (pt) processo de preparo de derivados de amino-benzofurano
MX2019006766A (es) Aditivos para combustibles de amonio cuaternario.
MX2014011752A (es) Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
MX2014002106A (es) Composicion ionomerica antimicrobiana y usos de la misma.
MX2016005829A (es) Procedimiento para la preparacion de iopamidol.
PE20090956A1 (es) PROCESO PARA LA OBTENCION DE DERIVADOS DE PIRIDO [2,1-a] - ISOQUINOLINA
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR098484A1 (es) Insecticidas de 1-aril-3-alquilpirazol
CO6290758A2 (es) Proceso para la elaboracion de [fenilsulfanilfenil]piperidinas
PE20142331A1 (es) Metodo para preparar un compuesto mediante la reaccion de adicion de michael novedosa usando agua o varios acidos como aditivo
MX344516B (es) Bifenoles halogenados como agentes antibacterianos.
CL2008003086A1 (es) Proceso para preparar 2-(fenilo sustituido-2-hidroxi-etil) carbamatos por reduccion de un alfa-alcohol ester protegido.
BR9809473A (pt) Mistura fungida, e, processo para controlar fungos nocivos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed